特意查了一下，“是阳就抗”，庄辉引用的美国文献，原来

不想死啊

是美国传染病学会（不是AASLD协会）几个人写的东西，最多也就是代表协会的某些观点而言，这类文章网上很多，随意性和争议性都很大，是探讨性文章。关键是，它根本不是AASLD （美国肝病协会）的专业权威报告。AASLD才是真正的肝病研究权威，他们的东西才具有很高的参考价值。别的不多说了，英文好的，自己读一下原文摘要，我也懒得一一翻译了。



Simplifying Treatment Criteria in Chronic Hepatitis B: Reducing Barriers to Elimination

Robert J Wong  1   2 , Harvey W Kaufman  3 , Justin K Niles  3 , Hema Kapoor  3 , Robert G Gish  4
Affiliations  expand
PMID: 35594550  DOI: 10.1093/cid/ciac385
Abstract

Background: Early, sustained hepatitis B virus (HBV) DNA suppression reduces long-term risks of hepatocellular carcinoma. Chronic hepatitis B (CHB) treatment criteria are complex. Simplifying criteria will improve timely linkage-to-therapy. We evaluated treatment eligibility patterns among U.S. CHB patients and propose stepwise simplification of CHB treatment criteria.

Methods: Using 2016-2020 Quest Diagnostics data, treatment eligibility among CHB patients (two positive HBV tests [HBsAg, HBeAg, or HBV DNA] ≥6 months apart) was evaluated using American Association for the Study of Liver Disease (AASLD), European Association for Study of the Liver (EASL), Asian Pacific Association for Study of the Liver (APASL), and Asian American Treatment Algorithm (AATA) criteria.

Results: Among 84,916 CHB patients, 6.7%, 6.2%, 5.8%, and 16.4% met AASLD, EASL, APASL, and AATA criteria, respectively. Among treatment-ineligible CHB patients, proportion with significant fibrosis (AST platelet ratio index >0.5) were 10.4%, 10.4%, 10.8%, and 7.7% based on AASLD, EASL, APASL, and AATA, respectively. In the proposed treatment simplification, proportion of CHB patients eligible for therapy increased from 10.3% for step 1 (HBV DNA >20,000 IU/mL, elevated ALT) to 14.1% for step 2 (HBV >2,000 IU/mL, elevated ALT), 33.5% for step 3 (HBV DNA >2,000 IU/mL, any ALT), and 87.2% for step 4 (detectable HBV DNA, any ALT).

Conclusions: A large proportion of CHB patients not meeting established treatment criteria have significant fibrosis. Simplifying criteria to treat all patients with detectable HBV DNA will reduce complexity and heterogeneity in assessing treatment eligibility, improving treatment rates and progress towards HBV elimination.

Keywords: AASLD; EASL; antivirals; hepatitis B virus; treatment eligibility.

© The Author(s) 2022. Published by Oxford University Press on behalf of the Infectious Diseases Society of America. All rights reserved. For permissions, please e-mail: [email protected].

ematrix

常识：
乙肝是传染病，属于传染病学下面的肝病传染病分支
乙肝也属于肝病

传染病学会发表关于乙肝的研究报告，你说正经不正经，山寨不山寨，权威不权威

中国的乙肝防治指南，发表单位是：中华医学会传染病学分会  中华医学会肝病学分会

前网红上海张医生，华山医院传染科主任，曾经担任上海市新冠肺炎医疗救治专家组组长，结果咋样都知道了。张医生主修的传染病，是肝病传染病方向，却去担任呼吸道传染病组长，搞砸了。
要学知识 要有文化

tim889

ematrix 发表于 2022-8-2 15:02
常识：
乙肝是传染病，属于传染病学下面的肝病传染病分支
乙肝也属于肝病

山不山寨 权不权威 都是你说了算。还传染病学会呢。哪里来的传染病学会？这些组织的全称你都拼不出来吧？哈哈哈哈

tim889

这篇文章根本不是什么指南。事实上Hepatitis B Foundation是主要提供信息的非盈利组织，自己从不发布什么指南。Hep B foundation的主页上列举的都是EASL，AASLD和WHO的指南（https://www.hepb.org/treatment-a ... linical-guidelines/）。美国的医生主要参考的指南只有EASL和AASLD，偶尔会参考亚太的

这篇文章其实就是在吉利德赞助下 Rob Wong牵头和美国一家叫Quest Diagnostics做检测的公司和Hepatitis B Foundation的Robert G Gish合作研究了一下不同指南下符合治疗的人群的百分比，然后自己提出了四种简化标准，报告了一下每种标准下的符合治疗的人群的百分比是多少，仅此而已。就是数个数。文章的目的压根就不是说提出一个固定新标准。

有胡乱解读的专家。有不学无术，喜欢成天看所谓的专家胡乱解读的妄人战友。这些人自己看不懂原文，连翻译软件都懒得读完的，并喜欢大言不惭，成天跑论坛胡说八道。被人指出了就只会人身攻击。

tim889

自己看看这篇文章的作者都是收了谁的钱，我没有证据证明他们的目的，我不会胡说。但大家可以动脑子想想 写这文章的背后可能的目的是啥。


Notes
Financial support. This study was supported by Gilead Sciences (investigator-initiated research study grant).
Potential conflicts of interest. R. J. W. has received funding (to his insti- tution) from Gilead Sciences, and has served as a consultant and on the ad- visory board for Gilead Sciences. H. W. K., J. K. N., and H. K. are employees of and H. W. K. and H. K. own stock in Quest Diagnostics. R. G. G. reports grants received from Gilead Sciences; has served as an advisor or consultant to Abbott, AbbVie, Altimunne, Antios, Arrowhead, Dynavax, Eiger, Eisai, Enyo, Genentech, Genlantis, Gerson Lehrman Group, Gilead Sciences, Helios, HepaTX, HepQuant, Intercept, Janssen, Merck, Pfizer, Topography Health, Venatorx, Prodigy, Fibronostics, Fujifilm/Wako, Perspectum, Quest, and Sonic Incytes; has served on the data safety mon- itoring board for Altimmune, Arrowhead, CymaBay Therapeutics, and Durect; has served on the speaker’s bureau for AbbVie, BMS, Eisai, Genentech, Gilead Sciences, and Intercept; is a minor stock shareholder of RiboSciences and CoCrystal; and has received stock options from Eiger, Genlantis, HepQuant, and AngioCrine. All authors have submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Conflicts that the editors consider relevant to the content of the manuscript have been disclosed.

tim889

不想死啊 发表于 2022-8-1 16:36
是美国传染病学会（不是AASLD协会）几个人写的东西，最多也就是代表协会的某些观点而言，这类文章网上很多 ...

所以说你的直觉是对的

ematrix

11111

ematrix

11111

ematrix

11111

ematrix

乙肝是不是归属于传染病学会的研究范围？
你回答一下

楼主觉得肝病学会才是正统，传染病学会没资格写乙肝的东西，请问你这是赞同的什么直觉？